FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The safety profile of Tecentriq with mFOLFOX6 was consistent with previous studies of Tecentriq and mFOLFOX6.

  60% confidence

• Until now the adjuvant standard of care for stage III colon cancer has not differed by mismatch repair status; atezolizumab plus chemotherapy is a practice-changing regimen that reduces the risk of recurrence or death by 50%.

  60% confidence

• Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years.

  60% confidence

• The approval provides a new adjuvant treatment option for stage III dMMR colon cancer patients at high risk of recurrence, and Tecentriq plus chemotherapy has the potential to become the new standard of care as the first approved immunotherapy-based regimen in this setting.

  60% confidence

Citado nestas reportagens da Via News

• Oncology's Busy Autumn: A Cash-Burning Drugmaker Awaits Its Verdict While AI Promises Faster Medicines →
• Oncology's Next Wave Meets Its Test: Summit's Nov. 14 Ivonescimab Decision, a Record Loss, and AI Claims That Are Still Forecasts →
• Oncology's Three Bets: New Drug Types, AI-Built Medicines and a $5.8 Billion Care Deal, and the Cash Behind One Closely Watched Drug →